DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Dostinex (Cabergoline) - Summary

 
 



DOSTINEX SUMMARY

DOSTINEX®
cabergoline tablets

DOSTINEX Tablets contain cabergoline, a dopamine receptor agonist.

DOSTINEX Tablets are indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas.


See all Dostinex indications & dosage >>

NEWS HIGHLIGHTS

Published Studies Related to Dostinex (Cabergoline)

Effectiveness of short-term maintenance treatment with cabergoline in microadenoma-related and idiopathic hyperprolactinemia. [2010.11]
OBJECTIVE: This study aimed to determine the effectiveness of short-term maintenance treatment with cabergoline and to find out minimum effective dosage of cabergoline during maintenance treatment for patients with microadenoma-related and idiopathic hyperprolactinemia... CONCLUSIONS: The results indicate that short maintenance treatment in idiopathic and microadenoma-related hyperprolactinemia seems as effective as long maintenance treatment in the present study. But, further studies with larger study population and longer follow-up period are needed to make a decision about early treatment withdrawal. Also, during the maintenance treatment administration of medicine to patients should be tapered down to the lowest dose that will maintain prolactin levels normal.

Cabergoline versus bromocriptine for symptomatic treatment of premenstrual mastalgia: a randomised, open-label study. [2010.06]
OBJECTIVE: To compare the effectiveness and side effects of cabergoline with bromocriptine for the symptomatic treatment of cyclic mastalgia as a part of the premenstrual syndrome... CONCLUSIONS: Cabergoline is as effective as bromocriptine for the treatment of cyclic mastalgia but has minimal side effects compared to bromocriptine. Copyright 2010 Elsevier Ireland Ltd. All rights reserved.

A comparison of bromocriptine & cabergoline on fertility outcome of hyperprolactinemic infertile women undergoing intrauterine insemination. [2010.05]
BACKGROUND & OBJECTIVES: The aim of this study was to compare the effects of bromocriptine versus cabergoline on pregnancy in hyperprolactinaemic infertile women... CONCLUSION: Our results suggest that cabergoline treatment in infertile women with prolactinemia is more effective. It lowers prolactin with better tolerability and much more effective in the achievement of pregnancy.

Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. [2007.08]
CONTEXT: Ovarian hyperstimulation syndrome (OHSS) results from increased vascular permeability (VP) caused by ovarian hypersecretion of vascular endothelial growth factor (VEGF), which activates its receptor-2. In animals, the dopamine receptor 2 agonist cabergoline (Cb2) inactivates VEGF receptor-2 and prevents increased VP. OBJECTIVE: Our objective was to test whether Cb2 reduces VP and prevents OHSS in humans... CONCLUSIONS: Given that Cb2 is a well-established and safe medication, this study provides proof of concept for the use of dopamine agonists in the prevention of OHSS in women undergoing assisted reproduction.

Cabergoline compared to levodopa in the treatment of patients with severe restless legs syndrome: Results from a multi-center, randomized, active controlled trial. [2007.04.15]
We report the first large-scale double-blind, randomly assigned study to compare two active dopaminergic therapies for Restless Legs Syndrome (RLS), the dopamine agonist cabergoline (CAB) and levodopa/benserazide (levodopa). Patients with idiopathic RLS were treated with fixed daily doses of 2 or 3 mg CAB or 200 or 300 mg levodopa for 30 weeks...

more studies >>

Clinical Trials Related to Dostinex (Cabergoline)

Bioequivalence Study of Cabergoline Tablets and Dostinex Under Fed Conditions [Completed]

Bioequivalence Study of Cabergoline Tablets and Dostinex Under Fasting Conditions [Completed]

Efficacy of Rapid Escalation of Cabergoline in Comparison to Conventional Dosing in Prolactin Secreting Macroadenomas. [Recruiting]

Cardiac Valve Complications in Prolactinomas Treated With Cabergoline [Completed]
Dopamine agonists are first-line agents for the treatment of prolactinomas (1) and Parkinson's disease (2). There is evidence supporting a causal relationship between the occurrence of drug-induced "restrictive" valvular heart disease and treatment with pergolide (3): in several cases, the valvulopathy improved when pergolide was discontinued (4). Valvular heart damage has also been reported with the ergot-derived dopamine agonists bromocriptine and cabergoline (5,6).

Two recent studies (7,8) have further demonstrated that both pergolide and cabergoline are associated with an increased risk of new cardiac valve regurgitation in patients treated for Parkinson's disease.

The valvular abnormalities seen with ergot-derived dopamine agonists are similar to those observed in patients receiving ergot alkaloid agents (such as ergotamine and methysergide) in the treatment of migraine, or fenfluramine and dexfenfluramine in the treatment of obesity. These abnormalities also closely resemble carcinoid-related valvulopathies (9).

Cardiac valve disease has never been reported in patients with prolactinomas who require treatment with dopamine-agonists even life-long (1). At variance with patients with Parkinson's disease, patients with prolactinomas are younger and are treated with an average dose of dopamine-agonists that is significantly lower (median bromocriptine dose 5 mg/day and median cabergoline dose 1 mg/week). Because of the young age of treatment beginning (most patients with microprolactinomas start dopamine-agonist treatment in early adulthood), treatment might be continued for over 3 decades: the cumulative risk of low doses of dopamine agonists for such a long period of treatment is currently unknown.

To assess the prevalence of cardiac valve disease in patients treated with cabergoline, we wish to perform an echocardiography screening in a large representative sample of patients with prolactinoma who were treated with cabergoline for at least 12 months and in a group of control subjects recruited prospectively. We wish to evaluate the severity of regurgitation for the mitral, aortic, and tricuspid valves. Changes in cardiac valve apparatus was compared with treatment duration and cumulative cabergoline dose.

Cabergoline in Metastatic Breast Cancer [Recruiting]
Prolactin is a hormone produced in the pituitary gland. Previous studies have revealed that elevated levels of the hormone prolactin might be associated with an increased risk of breast cancer. Cabergoline has been shown to lower prolactin levels in the blood.

The purpose of this study is to evaluate the effectiveness of cabergoline in treating metastatic breast cancer disease in those who test positive for the prolactin receptor.

more trials >>

Reports of Suspected Dostinex (Cabergoline) Side Effects

Blood Prolactin Increased (9)Drug Ineffective (7)Dyspnoea (7)Prolactinoma (6)Maternal Exposure Timing Unspecified (6)Craniopharyngioma (6)Breast Pain (5)Nausea (5)Headache (4)Fatigue (4)more >>


PATIENT REVIEWS / RATINGS / COMMENTS

Based on a total of 3 ratings/reviews, Dostinex has an overall score of 7.67. The effectiveness score is 8.67 and the side effect score is 7.33. The scores are on ten point scale: 10 - best, 1 - worst.
 

Dostinex review by 34 year old female patient

  Rating
Overall rating:  
Effectiveness:   Highly Effective
Side effects:   Mild Side Effects
  
Treatment Info
Condition / reason:   prolactinoma
Dosage & duration:   50 mcg or mg (one of the smallest doses) taken 1 x weekly for the period of 4 years
Other conditions:   none
Other drugs taken:   none
  
Reported Results
Benefits:   reduced prolactin levels to within normal range. No longer experienced Amenorrhea and galactorrhea.
Side effects:   Slightly dizzy right after taking. Side effect not noticeable if taken right before bedtime. Added bonus of increased libido.
Comments:   Take 1 tablet once a week (those with larger adenomas may need to take more frequently)

 

Dostinex review by 31 year old male patient

  Rating
Overall rating:  
Effectiveness:   Considerably Effective
Side effects:   Mild Side Effects
  
Treatment Info
Condition / reason:   prolactin inhibitor
Dosage & duration:   .25 mg taken 2/wk for the period of 6 weeks
Other conditions:   none
Other drugs taken:   none
  
Reported Results
Benefits:   Treatment was not for traditional drug use. It was for sexual experimentation--to see if male orgasm response times were decreased and sexual desire after orgasm remained. This did work.
Side effects:   Mild fatigue and general apathy.
Comments:   Took .25mg of Cabergoline 2 times per week for 6 weeks. During this time, the test was to see if time between orgasms decreased and if sexual desire remained. Test was successful.

 

Dostinex review by 31 year old male patient

  Rating
Overall rating:  
Effectiveness:   Considerably Effective
Side effects:   Mild Side Effects
  
Treatment Info
Condition / reason:   prolactin inhibitor
Dosage & duration:   .25 mg taken 2/wk for the period of 6 weeks
Other conditions:   none
Other drugs taken:   none
  
Reported Results
Benefits:   Treatment was not for traditional drug use. It was for sexual experimentation--to see if male orgasm response times were decreased and sexual desire after orgasm remained. This did work.
Side effects:   Mild fatigue and general apathy.
Comments:   Took .25mg of Cabergoline 2 times per week for 6 weeks. During this time, the test was to see if time between orgasms decreased and if sexual desire remained. Test was successful.

See all Dostinex reviews / ratings >>

Page last updated: 2011-12-09

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014